samedan logo

home > news > detailed info

DFE Pharma opens its new Center of Excellence in India to provide fast-track formulation services

DFE Pharma

Hyderabad, India - May 26th, 2022 - DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, today announced the launch of its new Center of Excellence “Closer to the Formulator” (C2F) in Hyderabad, India. The C2F center is based in Genome Valley, a hub of major Indian and global (bio)pharmaceutical companies and renowned research organizations. C2F helps pharmaceutical companies to shorten the time from a concept to a finished commercial product through expertise in all phases of pharmaceutical development.

Pharmaceutical companies face increasing challenges, such as developing robust formulations which can be scaled up for high-speed production and first launched in the market. Smooth regulatory processes depend on decisions made in the development phase. ‘First-time right’ formulations are essential for success in the highly competitive market. Reducing cost and time of development can also allow affordable and new medicines to reach more patients, as advocated by national and regional policies such as the Jan Aushadi1 initiative in India or the EU pharmaceutical strategy2.

“Our new 1200m2 C2F center of excellence offers cutting-edge capabilities and resources to improve product development globally, while also integrating hardware and data management software,” explains Dr. Anilkumar S. Gandhi, Director of the C2F center. “Our services result in robust formulations, utilizing top-level excipient expertise transferrable to scale-up. We aim to further collaborate with our customers in this new center to combine the joint formulation expertise.”

The services offered by this new state-of-the-art facility are mainly focused on oral solid dosage forms, comprising all types of pre-registration work including development, scale-up, and technology transfer. Formulation support includes specialized dosage forms such as orally disintegrating, effervescent, chewable, and sublingual tablets, minitablets, etc. C2F capabilities also support efficiency projects such as conversion from wet granulation to direct compression.

The center works with the active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs. The equipment covers an instrumented tablet press, an automated capsule filling machine, a tablet coater, a blister packaging machine, stability chambers, and state-of-the-art analytical equipment. The C2F offering can provide pharmaceutical companies with multiple advantages such as significantly lowering the number of development cycles, for example, and reducing formulation costs when launching a medicine.

Speaking about C2F, Martti Hedman, CEO of DFE Pharma added: “DFE Pharma has made a multimillion-euro investment in the new Center of Excellence in Hyderabad. Our overall goal is to help the global and Indian pharmaceutical industry to launch new products fast, at a low cost, and always first-time-right. This new Center of Excellence demonstrates how DFE Pharma anticipates trends and innovations to increase patient’s access to safe, high-quality medicines.”

Honorable Minister Mr. K.T. Rama Rao, Cabinet Minister for IT, Industries & Commerce, Municipal Administration & Urban Departments of Telangana government (India) said: "I'm delighted to welcome DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions in Genome Valley, Hyderabad. We are happy to support and facilitate the establishment of “Closer to the Formulator” (C2F) with the major objective of helping pharma companies to move up the value chain. The Government of Telangana will work with DFE Pharma to ensure that Life Sciences companies in the state leverage from this facility."

To find out more, please visit or email for further information.

1. Pharmaceutical & Medical Devices Bureau of India (PMDBI), Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana (PMBJP)
2. European Commission, A pharmaceutical strategy for Europe,
phone +49 2823 9288 770
email Klever Strasse 187 P.O. Box 20 21 20 47568 Goch
Print this page
Send to a friend
News and Press Releases

Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom

SHORT HILLS, NJ. June 16, 2022--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced it entered into an agreement with PCI Pharma Services (PCI), a leading integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United Kingdom (UK) for lenzilumab. Under the agreement, PCI will purchase lenzilumab for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19.
More info >>

White Papers

Optimize your Biologic’s Analytical Program for Greater Risk Reduction


Analytical methods are used throughout upstream and downstream processes to help ensure the desired molecule is being produced with the desired purity. In addition to having the right molecule, quality must be confirmed in terms of glycosylation, oxidation, aggregates, activity and concentration. The analytical package must also ensure that all impurities from the manufacturing process and environment are consistently removed.
More info >>

Industry Events

Connect in Pharma

14-15 September 2022, Plaexpo, Geneva, Switzerland

The new event driving innovation for pharma and biopharma businesses, Connect in Pharma will unite key players in Pharmaceutical and Biopharmaceutical packaging and production in Geneva on 14 – 15 September 2022.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement